News

News
MSD says subcutaneous Keytruda matches IV form

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

News
Zhiyong Lu, senior investigator NIH/NLM

NIH algorithm matches patients to clinical trials

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of volunteers into clinical trials, aiming to solve a major obstacle in clin